Empowering Cancer-Specific Immunotherapy For Aggressive Tumors

Signal to your immune system: you’ve had it with cancer

Cancer kills. But it can only do so by evading the immune response. Indeed, in most individuals the immune system detects and destroys cells that could become cancerous every single day. To create an established tumor, cancerous cells must flip the switch to turn the immune system off.

SIRPant Immunotherapeutics takes on the challenge posed by cancer directly. Leveraging our deep understanding of the biology of myeloid cells—the cells that drive immune responses—SIRPant is spearheading the development of therapeutics that flip the switch back on.

SIRPant developed a cellular immunotherapy against cancer (SIRPant-M™) that promotes a polyclonal anti-tumor immune response that endures both in TIME (resulting in immune memory that prevents recurrence) and in SPACE (resulting in clearance of metastases) to achieve durable elimination of cancerous cells throughout the body.

It has not escaped our notice that cancer is only one instance of pathology caused by immune dysfunction. Many of the remaining challenges in immunology involve immune responses gone awry. In cases of immune hypo-activity (as occurs in cancer and chronic infections) or immune hyper-activity (as occurs in autoimmunity, allergy, and anaphylaxis) the immune response has been mobilized but has been subsequently either turned off or turned up far too high. Macrophages play a key role in maintaining this dysfunction. But when rightly instructed, they also have the potential to dramatically reverse the dysfunction. And that is what SIRPant aims to do, addressing cancer first and then the remaining immunopathologies.

Who We Are

SIRPant Immunotherapeutics focuses on the cell biology of the immune response. As an early-stage company, our mission is to discover, develop, and implement transformative cell-based therapies for the treatment of cancer and life-altering immunopathology.

Our novel technology focuses on macrophages, requires no genetic modification, and leverages intrinsic control mechanisms within your immune cells to overcome common limitations of other cellular immunotherapies. This results in a highly modulatory platform capable of treating a host of immunological and oncological diseases.

The solution to a problem is sometimes found not by staring at the problem itself but by getting at its underlying cause. Cancer is fundamentally an immunological problem. Immunological dysfunction is fundamentally a cell biological problem. We do cell biology.

At SIRPant, we harness the body’s own immune cells and re-educate them to elicit a response against cancer. While avoiding the introduction of genetic alterations that can cause untoward consequences, our products attack the cancer on their own and rally other immune cells to do the same.

Utilizing our technology platform, we developed a first-in-class cell therapy (SIRPant-M™) that can target any cancer without requiring prior cancer marker identification and characterization. SIRPant-M™ employs a proprietary macrophage activation solution – PhagoAct™ – to license immune cells for recognizing and eliminating cancer. Much like a vaccine, SIRPant-M™ mobilizes both the cellular and humoral arms of the immune system to seek out and kill cancer cells throughout your body, resulting in long-lasting immune memory against cancer.

NEWS & EVENTS

Contact

Sign-up for News Updates
This field is for validation purposes and should be left unchanged.